Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
FLT3LG Biologics Sequence Review Report 2026: Fms-related tyrosine kinase 3 ligand Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FLT3LG protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGFBP3 Biologics Sequence Review Report 2026: Fibroblast growth factor-binding protein 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFBP3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGFBP2 Biologics Sequence Review Report 2026: Fibroblast growth factor-binding protein 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFBP2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGFBP1 Biologics Sequence Review Report 2026: Fibroblast growth factor-binding protein 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGFBP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF8 Biologics Sequence Review Report 2026: Fibroblast growth factor 8 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF23 Biologics Sequence Review Report 2026: Fibroblast growth factor 23 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF23 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF22 Biologics Sequence Review Report 2026: Fibroblast growth factor 22 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF20 Biologics Sequence Review Report 2026: Fibroblast growth factor 20 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF14 Biologics Sequence Review Report 2026: Fibroblast growth factor 14 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF13 Biologics Sequence Review Report 2026: Fibroblast growth factor 13 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF13 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF12 Biologics Sequence Review Report 2026: Fibroblast growth factor 12 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF12 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF11 Biologics Sequence Review Report 2026: Fibroblast growth factor 11 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of FGF11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
255
256
257
258
259
>>
1670
>